We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AstraZeneca and The University of Manchester Work with DxS on a Clinical Pharmacology Collaboration

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "AstraZeneca and The University of Manchester Work with DxS on a Clinical Pharmacology Collaboration "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

DxS has been selected by AstraZeneca PLC and The University of Manchester (Paterson Institute) to welcome a Clinical Research Fellow supported by AstraZeneca and Cancer Research UK during part of a project, aiming to identify circulating DNA tumour markers in patients’ blood.
DxS will assist the research fellow in the development of mutation detection assays using its Scorpions™ and ARMS™ Technologies.

These offer selective tests that show significant improvement in detection of low-level mutations over traditional sequencing-based techniques.

The assays can detect mutations in circulating DNA in blood, which is essential to allow the determination of the molecular profile of a tumour through methods other than an invasive biopsy.
The initial focus of the three year project will be to develop assays for genes which show prevalent mutations in cancer. 
Dr Andrew Hughes, Director of Discovery Medicine at AstraZeneca with Professor Caroline Dive, Clinical & Experimental Pharmacology, Paterson Institute comment, "With their expertise in ARMS allele specific PCR and their proven capability in the development of oncology mutation tests, DxS was a natural choice for a partner in this key diagnostic project looking at the identification of blood borne biomarkers for mechanism-based therapies."